German Merck and Pfizer are now following in the footsteps of Bristol-Myers Squibb (BMS), Merck & Co, and Roche with their revolutionary cancer immunotherapies. Bavencio, a human anti-PD-L1 ...

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free ...

FRANKFURT, March 6 (Xinhua) -- German science and technology giant Merck Group reported a return to growth in 2024, with net sales rising 0.8 percent to 21.16 billion euros (22.8 billion U.S. dollars) ...

FRANKFURT, Feb 18 (Reuters) - Germany's Merck KGaA (MRCG.DE), opens new tab said on Tuesday its lab equipment division and its pharmaceuticals division would be under new leadership from June but ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.

Merck KGaA said it appointed two new members to the executive board for the life science and healthcare business sectors, along with a newly-created chief people officer role. The German ...

There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA.

Full Year 2024 Results Key Financial Results Revenue: €21.2b (flat on FY 2023). Net ...

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

FRANKFURT, March 6 (Xinhua) -- German science and technology giant Merck Group reported a return to growth in 2024, with net sales rising 0.8 percent to 21.16 billion euros (22.8 billion U.S ...